Intellia Therapeutics Receives FDA Priority Review for Lonvoz
Intellia Therapeutics (NTLA) saw an increase in premarket trading after the U.S. Food and Drug Administration granted priority review status to its marketing application for lonvo-z, a one-time treatment targeting hereditary angioedema, a rare genetic disorder. The FDA accepted Intellia's Biologics License Application under the Priority Review designation, which is intended to expedite the evaluation of drugs that offer significant improvements in safety or effectiveness over existing therapies. This move signals regulatory confidence in lonvo-z’s potential and could lead to an earlier approval decision than standard review timelines. The priority status may enhance investor sentiment toward Intellia's pipeline and increase market interest, particularly as it represents a milestone for the company's gene-editing platform.
Tickers: $NTLA
Topics: biotech drug development hereditary angioedema rare diseases